6.45
1.77 (37.82%)
| Penutupan Terdahulu | 4.68 |
| Buka | 5.75 |
| Jumlah Dagangan | 2,604,898 |
| Purata Dagangan (3B) | 398,624 |
| Modal Pasaran | 155,830,960 |
| Harga / Jualan (P/S) | 1.49 |
| Harga / Buku (P/B) | 7.44 |
| Julat 52 Minggu |
| Margin Keuntungan | -27.34% |
| Margin Operasi (TTM) | -21.71% |
| EPS Cair (TTM) | -0.840 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 367.92% |
| Nisbah Semasa (MRQ) | 2.32 |
| Aliran Tunai Operasi (OCF TTM) | -14.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.11 M |
| Pulangan Atas Aset (ROA TTM) | -19.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -117.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Exagen Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 5.0 |
| Purata | 1.83 |
|
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.82% |
| % Dimiliki oleh Institusi | 45.44% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |